Form 8-K CervoMed Inc. For: Sep 10

Thu, 10 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260910/27048449.html

CervoMed nfvPPA trial data to be presented at ISFTD meeting

Thu, 10 Sep 2026 07:30:35 -0400

CervoMed Inc. (NASDAQ: CRVO) announced that initial biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) have been accepted as a late-breaking oral presentation at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting in Philadelphia, Pennsylvania, scheduled for October 8-11, 2026.

The presentation, placed in the Plenary 6 "Hot Topics" session on October 11, 2026, will highlight 12-week data for two plasma biomarkers — neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) — from at least 22 of the trial's 25 enrolled participants. The abstract submitted for acceptance described data

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT

Thu, 10 Sep 2026 07:30:00 -0400

12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting

nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union

BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral, small molecule, drug candidate targeting critical disease processes underlying degenerative disorders of the brain, will be featured in a late-breaking oral presentation at the International Society of

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT

Thu, 10 Sep 2026 07:30:00 -0400

12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting

nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union

CervoMed to Participate in September Investor Conferences

Tue, 08 Sep 2026 07:30:00 -0400

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:

Cantor Global Healthcare Conference
Format: Fireside Chat & 1x1 Investor Meetings
Date: Friday, September 11, 2026
Time: 10:55 – 11:25 AM ET

Webcast Link:
https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1

H.C. Wainwright Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Date: Tuesday, September 15, 2026
Time: 4:00 – 4:30 PM ET

Webcast Link:

CervoMed to Participate in September Investor Conferences

Tue, 08 Sep 2026 07:30:00 -0400

Cantor Global Healthcare Conference
Format: Fireside Chat & 1x1 Investor Meetings
Date: Friday, September 11, 2026
Time: 10:55 – 11:25 AM ET

Webcast Link:
https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1

H.C. Wainwright Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Date: Tuesday, September 15, 2026
Time: 4:00 – 4:30 PM ET

Webcast Link:

Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932117.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932117.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929129.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929129.html

Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26927031.html

Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26927031.html

Form SCHEDULE 13G CervoMed Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926160.html

Form SCHEDULE 13G CervoMed Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926160.html

CervoMed (CRVO) PT Lowered to $12 at Jones Trading

Mon, 10 Aug 2026 16:36:13 -0400

Jones Trading analyst Boris Peaker lowered the price target on CervoMed (NASDAQ: CRVO) to $12.00 (from $20.00) while maintaining a Buy rating.

Form 8-K CervoMed Inc. For: Aug 10

Mon, 10 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26897867.html

Form 8-K CervoMed Inc. For: Aug 10

Mon, 10 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26897867.html

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Mon, 10 Aug 2026 07:30:00 -0400

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB)

Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in DLB

New analyses presented at the Alzheimer’s Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial

Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15^th International Conference on Frontotemporal Dementia

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Mon, 10 Aug 2026 07:30:00 -0400

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB)

Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in DLB

New analyses presented at the Alzheimer’s Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial

Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15^th International Conference on Frontotemporal Dementia

CervoMed (CRVO) PT Lowered to $18 at Canaccord

Mon, 10 Aug 2026 07:29:40 -0400
(Updated - August 10, 2026 7:29 AM EDT)
Canaccord analyst Sumant Kulkarni lowered the price target on CervoMed (NASDAQ: CRVO) to $18.00 (from $27.00) while maintaining a Buy rating.
The analyst commented: "CRVO recently announced that the United Kingdom (UK) has awarded the company's lead candidate, neflamapimod, an Innovation Passport under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). We view this designation, which is now highly selective, as robust and independent external validation of the product's immense potential in DLB. Recall CRVO has reached regulatory alignment on a Phase 3 design. So,

CervoMed (CRVO) PT Lowered to $18 at Canaccord

Mon, 10 Aug 2026 07:29:40 -0400
(Updated - August 10, 2026 7:29 AM EDT)
Canaccord analyst Sumant Kulkarni lowered the price target on CervoMed (NASDAQ: CRVO) to $18.00 (from $27.00) while maintaining a Buy rating.
The analyst commented: "CRVO recently announced that the United Kingdom (UK) has awarded the company's lead candidate, neflamapimod, an Innovation Passport under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). We view this designation, which is now highly selective, as robust and independent external validation of the product's immense potential in DLB. Recall CRVO has reached regulatory alignment on a Phase 3 design. So,

Form S-8 CervoMed Inc.

Fri, 07 Aug 2026 16:55:00 -0400
si-local-file:///var/storage/secattach/20260807/26891940.html

Form S-8 CervoMed Inc.

Fri, 07 Aug 2026 16:55:00 -0400
si-local-file:///var/storage/secattach/20260807/26891940.html

Form 10-Q CervoMed Inc. For: Jun 30

Fri, 07 Aug 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260807/26891467.html

Form 10-Q CervoMed Inc. For: Jun 30

Fri, 07 Aug 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260807/26891467.html

StreetInsider.com News Articles

Form 8-K CervoMed Inc. For: Sep 10

CervoMed nfvPPA trial data to be presented at ISFTD meeting

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT

CervoMed to Participate in September Investor Conferences

CervoMed to Participate in September Investor Conferences

Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.

Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.

Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP

Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP

Form SCHEDULE 13G CervoMed Inc. Filed by: ARMISTICE CAPITAL, LLC

Form SCHEDULE 13G CervoMed Inc. Filed by: ARMISTICE CAPITAL, LLC

CervoMed (CRVO) PT Lowered to $12 at Jones Trading

Form 8-K CervoMed Inc. For: Aug 10

Form 8-K CervoMed Inc. For: Aug 10

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed (CRVO) PT Lowered to $18 at Canaccord

CervoMed (CRVO) PT Lowered to $18 at Canaccord

Form S-8 CervoMed Inc.

Form S-8 CervoMed Inc.

Form 10-Q CervoMed Inc. For: Jun 30

Form 10-Q CervoMed Inc. For: Jun 30